Electronic supplement material

Supplementary table 1 Search strategies of electronic database

a. Se	arch strategy used in CENTRAL				
#1	MeSH descriptor: [Scleroderma, Systemic] explode all trees				
#2	(systemic sclerosis*):ti,ab,kw				
#3	(systemic scleroderma*):ti,ab,kw				
#4	(systemic*):ti,ab,kw AND (sclerosis*):ti,ab,kw				
#5	(sclerosis*):ti,ab,kw AND (systemic*):ti,ab,kw				
#6	(systemic*):ti,ab,kw AND (scleroderma*):ti,ab,kw				
#7	(scleroderma*):ti,ab,kw AND (systemic*):ti,ab,kw				
#8	#1 or #2 or #3 or #4 or #5 or #6 or #7				
#9	MeSH descriptor: [Cardiovascular Diseases] explode all trees				
#10	(cardiovascular disease):ti,ab,kw				
#11	(cardiovascular abnormalities):ti,ab,kw				
#12	MeSH descriptor: [Myocardial Infarction] explode all trees				
#13	(Myocardial infarction):ti,ab,kw				
#14	(Myocardial Ischemia):ti,ab,kw				
#15	MeSH descriptor: [Stroke] explode all trees				
#16	(stroke):ti,ab,kw				
#17	(cerebrovascular accident):ti,ab,kw				
#18	(cerebrovascular disorder):ti,ab,kw				
#19	MeSH descriptor: [Peripheral Vascular Diseases] explode all trees				
#20	(peripheral vascular disease):ti,ab,kw				
#21	#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20				
#22	MeSH descriptor: [Cohort Studies] explode all trees				
#23	(cohort studies):ti,ab,kw				
#24	#22 or #23				
#25	#8 and #21 and #24				

b. Se	arch strategy used in EMBASE					
#1	systemic sclerosis':ab,ti					
#2	systemic scleroderma':ab,ti					
#3	systemic:ab,ti AND sclerosis:ab,ti					
#4	sclerosis:ab,ti AND systemic:ab,ti					
#5	systemic:ab,ti AND scleroderma:ab,ti					
#6	scleroderma:ab,ti AND systemic:ab,ti					
#7	systemic sclerosis'/exp OR 'systemic sclerosis' OR (systemic AND ('sclerosis'/exp OR sclerosis))					
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7					
#9	cardiovascular disease'/exp OR 'cardiovascular disease' OR (('cardiovascular'/exp OR cardiovascular) AND ('disease'/exp OR disease))					
#10	cardiovascular disease':ab,ti					
#11	'cardiovascular abnormalities':ab,ti					
#12	myocardial infarction'/exp OR 'myocardial infarction' OR (myocardial AND ('infarction'/exp OR infarction))					
#13						
#14	myocardial ischemia':ab,ti					
#15	'stroke'/exp OR stroke					
#16	stroke:ab,ti					
#17	cerebrovascular accident':ab,ti					
#18	cerebrovascular disorder':ab,ti					
#19	peripheral vascular diseases'/exp OR 'peripheral vascular diseases' OR (peripheral AND vascular AND ('diseases'/exp OR diseases))					
#20	'peripheral vascular diseases':ab,ti					
#2.1	#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20					
#22	cohort study'/exp OR 'cohort study' OR (cohort AND ('study'/exp OR study))					
#23	'cohort study':ab,ti					
#24	#22 OR #23					
#25	#8 AND #21 AND #24					

c. S	Search strategy used in MEDLINE
#1	exp *Scleroderma, Systemic/
#2	systemic sclerosis.mp.
#3	systemic scleroderma.mp.
#4	systemic\$ sclerosis.mp.
#5	sclerosis\$ systemic.mp.
#6	systemic\$ scleroderma.mp.
#7	scleroderma\$ systemic.mp.
#8	1 or 2 or 3 or 4 or 5 or 6 or 7
#9	exp *Cardiovascular Diseases/
#10	cardiovascular disease.mp.
#11	cardiovascular abnormalities.mp.
#12	exp *Myocardial Infarction/
#13	myocardial infarction.mp.
#14	myocardial ischemia.mp.
#15	exp *Stroke/
#16	stroke.mp.
#17	cerebrovascular accident.mp.
#18	cerebrovascular disorder.mp.
#19	exp *Peripheral Vascular Diseases/
#20	peripheral vascular disease.mp.
#21	9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
#22	exp *Cohort Studies/
#23	cohort study.mp.
#24	22 or 23
#25	8 and 21 and 24

Supplementary table 2 Detail of adjustment for studies in the meta-analysis

a. HRs of stroke

Study	Unadjusted HR (95%CI)	No adjustment	Fully adjusted HR (95%CI)	Adjustment for covariates
Avina-	3.08 (2.14-4.44)	Matched on	2.35 (1.59-3.48)	Age, sex, entry time, number of
Zubieta		age, sex, entry		outpatient visits, health resource
,2016		time		utilization, glucocorticoids,
				comorbidities
Chiang,	1.44 (1.15-1.80)	Matched on	1.43 (1.12-1.83)	Age, sex, entry time, comorbidities
2013		age, sex, entry		(hypertension, diabetes, dyslipidemia,
		time,		chronic kidney disease, coronary artery
		comorbidity		disease, atrial fibrillation)
Man,	2.56 (1.58-4.14)	Matched on	2.61 (1.54-4.44)	Age, sex, entry time, BMI, smoking,
2013		age, sex, entry		medication (aspirin, NSAID and oral
		time		glucocorticoid), comorbidities
				(hypertension, diabetes, hyperlipidemia,
				atrial fibrillation)
Ying,	1.28 (1.11-1.47)	Matched on	1.21 (1.05-1.40)	Age, sex, race, smoking, status, VA site,
2019		age, sex, race,		medication (aspirin, non-steroidal anti-
		smoking,		inflammatory drugs, statins),
		status, VA site		comorbidities (atrial fibrillation,
				hypertension, diabetes mellitus, non-
				cerebrovascular atherosclerotic disease,
				hyperlipidemia), Medicare enrollment
Butt,	1.28 (1.04-1.58)	Matched on	1.13 (0.90-1.42)	Age, sex, medication (ASA, NSAID,
2019		age, sex		glucocorticoids, statins, OAC and
				platelet inhibitors), comorbidities

b. HRs of myocardial infarction

Study	Unadjusted HR (95%CI)	No adjustment	Fully adjusted HR (95%CI)	Adjustment for covariates
Avina- Zubieta , 2016	4.26 (3.17-5.73)	Matched on age, sex, entry time	3.49 (2.52-4.83)	Age, sex, entry time, number of outpatient visits, health resource utilization, glucocorticoids, diabetes medication, comorbidities
Chu, 2013	2.40 (1.57-3.67)	Matched on age, sex, comorbidity	2.45 (1.60-3.75)	Age, sex, comorbidities (hypertension, diabetes, coronary artery disease, dyslipidemia, atrial fibrillation, peripheral arterial occlusive disease, chronic obstructive pulmonary disease, and chronic kidney disease)

Man,	1.97 (1.21-3.22)	Matched on	1.80 (1.07-3.05)	Age, sex, entry time, BMI, smoking,
2013		age, sex, entry		medication (aspirin, NSAID and oral
		time		glucocorticoid), comorbidities
				(hypertension, diabetes, hyperlipidemia)
Butt,	2.08 (1.65-2.64)	Matched on	1.91 (1.47-2.47)	Age, sex, medication (ASA, NSAID,
2019		age, sex		Glucocorticoids, statins, OAC and
				platelet inhibitors), comorbidities

c. HRs of cardiovascular disease


Study	Unadjusted HR (95%CI)	No adjustment	Fully adjusted HR (95%CI)	Adjustment for covariates
Avina-	3.54 (2.77-4.53)	Matched on	2.70 (2.07-3.51)	Age, sex, entry time, number of
Zubieta,		age, sex, entry		outpatient visits, health resource
2016		time		utilization, glucocorticoids,
				comorbidities
Hesselvig,	NA	NA	2.22 (1.99-2.48)	Age, calendar year, sex, socioeconomic
2018				status, medication, comorbidities

d. HRs of peripheral vascular disease

Study	Unadjusted HR (95%CI)	No adjustment	Fully adjusted HR (95%CI)	Adjustment for covariates
Man,	4.57 (2.99-7.01)	Matched on	4.35 (2.74-6.93)	Age, sex, entry time, BMI, smoking,
2013		age, sex, entry		medication (aspirin, NSAID and oral
		time		glucocorticoid), comorbidities
				(hypertension, diabetes, hyperlipidemia,
				atrial fibrillation)
Butt,	5.73 (4.63-7.09)	Matched on	5.54 (4.37-7.02)	Age, sex, medication (ASA, NSAID,
2019		age, sex		Glucocorticoids, statins, OAC and
				platelet inhibitors), comorbidities


Supplementary figure 1. Publication bias assessment

a. Funnel plot of the association between SSc and stroke



Egger's test: bias,4.15; 95%CI, -0.44 to 8.33; P=0.051.

b. Funnel plot of the association between SSc and myocardial infarction



Egger's test: bias,0.29; 95%CI, -17.73 to 18.31; P=0.951.